ARTICLE | Clinical News
Perceiva sirolimus: Completed Phase II enrollment
October 5, 2009 7:00 AM UTC
MacuSight completed enrollment of 62 previously treated patients in the placebo-controlled, dose-ranging, U.S. Phase II EMERALD trial evaluating subconjunctival injections of Perceiva in combination w...